A Physiological Function of Inflammation-Associated SerpinB2 Is Regulation of Adaptive Immunity

SerpinB2 (plasminogen activator inhibitor-2) is widely described as an inhibitor of urokinase plasminogen activator; however, SerpinB2−/− mice show no detectable increase in urokinase plasminogen activator activity. In this study, we describe an unexpected immune phenotype in SerpinB2−/− mice. After immunization with OVA in CFA, SerpinB2−/− mice made ≈6-fold more IgG2c and generated ≈2.5-fold more OVA-specific IFN-γ–secreting T cells than SerpinB2+/+ littermate controls. In SerpinB2+/+ mice, high inducible SerpinB2 expression was seen at the injection site and in macrophages low levels in draining lymph nodes and conventional dendritic cells, and no expression was seen in plasmacytoid dendritic, B, T, or NK cells. SerpinB2−/− macrophages promoted greater IFN-γ secretion from wild-type T cells in vivo and in vitro and, when stimulated with anti-CD40/IFN-γ or cultured with wild-type T cells in vitro, secreted more Th1-promoting cytokines than macrophages from littermate controls. Draining lymph node SerpinB2−/− myeloid APCs similarly secreted more Th1-promoting cytokines when cocultured with wild-type T cells. Regulation of Th1 responses thus appears to be a physiological function of inflammation-associated SerpinB2; an observation that may shed light on human inflammatory diseases like pre-eclampsia, lupus, asthma, scleroderma, and periodontitis, which are associated with SerpinB2 polymorphisms or dysregulated SerpinB2 expression.

[1]  B. Illades-Aguiar,et al.  A Functional Ser413/Ser413 PAI-2 Polymorphism Is Associated With Susceptibility and Damage Index Score in Systemic Lupus Erythematosus , 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[2]  M. Degli-Esposti,et al.  Graft-versus-host disease prevents the maturation of plasmacytoid dendritic cells , 2009, The Journal of Immunology.

[3]  F. Dammacco,et al.  Overexpression of interleukin‐12 and T helper 1 predominance in lupus nephritis , 2008, Clinical and experimental immunology.

[4]  S. Gaffen,et al.  A New Inflammatory Cytokine on the Block: Re-thinking Periodontal Disease and the Th1/Th2 Paradigm in the Context of Th17 Cells and IL-17 , 2008, Journal of dental research.

[5]  G. Heda,et al.  Role of tissue-type plasminogen activator in salicylic acid-induced sloughing of human corn tissue. , 2008, Journal of the American Podiatric Medical Association.

[6]  A. Suhrbier,et al.  SerpinB2 protection of retinoblastoma protein from calpain enhances tumor cell survival. , 2008, Cancer research.

[7]  M. Eisenacher,et al.  Gene expression in periodontal tissues following treatment , 2008, BMC Medical Genomics.

[8]  N. Buduneli,et al.  Gingival crevicular fluid PGE2, IL-1beta, t-PA, PAI-2 levels in type 2 diabetes and relationship with periodontal disease. , 2008, Clinical biochemistry.

[9]  David R. Croucher,et al.  Revisiting the biological roles of PAI2 (SERPINB2) in cancer , 2008, Nature Reviews Cancer.

[10]  A. Suhrbier,et al.  Kunjin replicon-based simian immunodeficiency virus gag vaccines , 2008, Vaccine.

[11]  Francesco Boin,et al.  T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease. , 2008, Arthritis and rheumatism.

[12]  J. Priatel,et al.  Critical role for IFN‐γ in natural killer cell‐mediated protection from diabetes , 2008 .

[13]  I. Scroyen,et al.  Deficiency of plasminogen activator inhibitor‐2 impairs nutritionally induced murine adipose tissue development , 2007, Journal of thrombosis and haemostasis : JTH.

[14]  R. Wilensky,et al.  The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation , 2007, Current opinion in cardiology.

[15]  Yee Hwa Yang,et al.  Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids , 2007, Proceedings of the National Academy of Sciences.

[16]  M. Neuenhahn,et al.  NF-κB Is a Negative Regulator of IL-1β Secretion as Revealed by Genetic and Pharmacological Inhibition of IKKβ , 2007, Cell.

[17]  Nicole Cloonan,et al.  Human Sin1 contains Ras-binding and pleckstrin homology domains and suppresses Ras signalling. , 2007, Cellular signalling.

[18]  B. León,et al.  Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. , 2007, Immunity.

[19]  Y. Sasaki,et al.  The role of the immune system in preeclampsia. , 2007, Molecular aspects of medicine.

[20]  A. Franx,et al.  Inflammatory Changes in Preeclampsia: Current Understanding of the Maternal Innate and Adaptive Immune Response , 2007, Obstetrical & gynecological survey.

[21]  C. Best-Aguilera,et al.  Genotype Ser413/Ser of PAI‐2 polymorphism Ser413/Cys is associated with anti‐phospholipid syndrome and systemic lupus erythematosus in a familial case: comparison with healthy controls , 2007, Scandinavian journal of rheumatology.

[22]  T. Poll,et al.  Plasminogen Activator Inhibitor Type-1-Deficient Mice Have an Enhanced IFN-γ Response to Lipopolysaccharide and Staphylococcal Enterotoxin B1 , 2006, The Journal of Immunology.

[23]  D. Harrich,et al.  SerpinB2 Is an Inducible Host Factor Involved in Enhancing HIV-1 Transcription and Replication* , 2006, Journal of Biological Chemistry.

[24]  L. Hawthorn,et al.  Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease. , 2006, Blood.

[25]  S. Abdulkadir,et al.  Effects of Histone Deacetylase Inhibitor (HDACi); Trichostatin-A (TSA) on the expression of housekeeping genes. , 2006, Molecular and cellular probes.

[26]  A. Giordano,et al.  Cytoplasmic and nuclear interaction between Rb family proteins and PAI-2: a physiological crosstalk in human corneal and conjunctival epithelial cells , 2006, Cell Death and Differentiation.

[27]  E. Kruithof,et al.  Evidence for serpinB2-independent protection from TNF-alpha-induced apoptosis. , 2005, Experimental cell research.

[28]  A. Hoffmann,et al.  Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis--CREB and NF-kappaB as key regulators. , 2005, Immunity.

[29]  S. Madoiwa,et al.  Protection of Plasminogen Activator Inhibitor-1-Deficient Mice from Nasal Allergy1 , 2005, The Journal of Immunology.

[30]  S. Lobov,et al.  Structural bases of the redox-dependent conformational switch in the serpin PAI-2. , 2004, Journal of molecular biology.

[31]  S. Smola,et al.  High plasminogen activator inhibitor type 2 expression is a hallmark of scleroderma fibroblasts in vitro , 2004, Experimental dermatology.

[32]  J. Whisstock,et al.  Human clade B serpins (ov-serpins) belong to a cohort of evolutionarily dispersed intracellular proteinase inhibitor clades that protect cells from promiscuous proteolysis , 2004, Cellular and Molecular Life Sciences CMLS.

[33]  J. Foekens,et al.  Predictive Impact of Urokinase-Type Plasminogen Activator , 2004, Cancer Research.

[34]  M. Gyetko,et al.  Urokinase-Deficient Mice Fail To Generate a Type 2 Immune Response following Schistosomal Antigen Challenge , 2004, Infection and Immunity.

[35]  T. Ulutin,et al.  PCR-RFLP Detection of PAI-2 Variants in Myocardial Infarction , 2003, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[36]  D. Harrich,et al.  Inhibition of Retinoblastoma Protein Degradation by Interaction with the Serpin Plasminogen Activator Inhibitor 2 via a Novel Consensus Motif , 2003, Molecular and Cellular Biology.

[37]  P. Robbins,et al.  TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis , 2003, Annals of the rheumatic diseases.

[38]  Xia Wang,et al.  Identification of interaction between PAI-2 and IRF-3. , 2003, Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica.

[39]  C. Sweep,et al.  Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. , 2002, American journal of obstetrics and gynecology.

[40]  R. Medcalf,et al.  Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation. , 2002, Blood.

[41]  B. Kinnby The Plasminogen Activating System in Periodontal Health and Disease , 2002, Biological chemistry.

[42]  N. Van Rooijen,et al.  CLODRONATE LIPOSOMES: PERSPECTIVES IN RESEARCH AND THERAPEUTICS , 2002, Journal of liposome research.

[43]  Mitsuaki Suzuki,et al.  Expansion of the Fraction of Th1 Cells in Women with Preeclampsia: Inverse Correlation between the Percentage of Th1 Cells and the Plasma Level of PAI‐2 , 2001, American journal of reproductive immunology.

[44]  T. Ninomiya,et al.  Predominance of Th1 immune response in diffuse proliferative lupus nephritis. , 2001, Arthritis and rheumatism.

[45]  R. Appelberg,et al.  Interleukin‐6 regulates the phenotype of the immune response to a tuberculosis subunit vaccine , 2001, Immunology.

[46]  J. Vassalli,et al.  Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice. , 2001, Cancer research.

[47]  D. Hume,et al.  Regulation of the plasminogen activator inhibitor‐2 (PAI‐2) gene in murine macrophages. Demonstration of a novel pattern of responsiveness to bacterial endotoxin , 1999, Journal of leukocyte biology.

[48]  M. Gyetko,et al.  Urokinase is required for T lymphocyte proliferation and activation in vitro. , 1999, The Journal of laboratory and clinical medicine.

[49]  R. Westrick,et al.  The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  N. Booth,et al.  Secretion of plasminogen activator inhibitor 2 by human peripheral blood monocytes occurs via an endoplasmic reticulum-golgi-independent pathway. , 1998, Experimental cell research.

[51]  P. Jensen,et al.  Regulation of the level and glycosylation state of plasminogen activator inhibitor type 2 during human keratinocyte differentiation. , 1998, Differentiation; research in biological diversity.

[52]  J. Dickinson,et al.  The Serine Proteinase Inhibitor (Serpin) Plasminogen Activation Inhibitor Type 2 Protects against Viral Cytopathic Effects by Constitutive Interferon α/β Priming , 1998, The Journal of experimental medicine.

[53]  C. Foy,et al.  PCR-RFLP Detection od PAI-2 Gene Variants: Prevelence in Ethnic Groups and Disease Relationship in patients Undergoing corony Angiography , 1997, Thrombosis and Haemostasis.

[54]  J. Gilabert,et al.  Decreased Expression of PAI-2 mRNA and Protein in Pregnancies Complicated with Intrauterine Fetal Growth Retardation , 1996, Thrombosis and Haemostasis.

[55]  T. Jensen,et al.  The Exon 3 Encoded Sequence of the Intracellular Serine Proteinase Inhibitor Plasminogen Activator Inhibitor 2 Is a Protein Binding Domain* , 1996, The Journal of Biological Chemistry.

[56]  M. Baker,et al.  Biological and clinical aspects of plasminogen activator inhibitor type 2. , 1995, Blood.

[57]  J. Dickinson,et al.  Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. , 1995, The Journal of biological chemistry.

[58]  N. Booth,et al.  Thrombin modulates synthesis of plasminogen activator inhibitor type 2 by human peripheral blood monocytes. , 1995, Blood.

[59]  H. Gan,et al.  Plasminogen activator inhibitor type 2 prevents programmed cell death of human macrophages infected with Mycobacterium avium, serovar 4. , 1995, Journal of immunology.

[60]  J. Alexander,et al.  The demonstration of an essential role for macrophages in the in vivo generation of IgG2a antibodies , 1994, Clinical and experimental immunology.

[61]  F. D’Acquisto,et al.  Annexin A1 and glucocorticoids as effectors of the resolution of inflammation , 2009, Nature Reviews Immunology.

[62]  Alberto Mantovani,et al.  Macrophage activation and polarization. , 2008, Frontiers in bioscience : a journal and virtual library.

[63]  M. Akahoshi,et al.  Th1/Th2 balance of SLE patients with lupus nephritis. , 2006, Rinsho byori. The Japanese journal of clinical pathology.

[64]  Xia Wang,et al.  Interaction of plasminogen activator inhibitor-2 and proteasome subunit, beta type 1. , 2004, Acta biochimica et biophysica Sinica.

[65]  Jingfan,et al.  Interaction of Plasminogen Activator Inhibitor-2 and Proteasome Subunit, Beta Type 1 , 2004 .

[66]  Y. Matsuda,et al.  Suppression of keratinocyte proliferation by plasminogen activator inhibitor-2. , 1999, The Journal of investigative dermatology.